The Vetr crowd downgraded their rating for Juno Therapeutics Inc JUNO on Thursday, from 4.5 stars (Strong Buy), issued 30 days go, to 1.5 stars (Strong Sell). At the time of the downgrade, crowd sentiment for Juno was edging positive, with 66 percent of Vetr user ratings bullish.
Vetr's downgrade on the pharmaceutical company comes after a bit of a selloff following the release of its earnings report on March 1. Juno posted revenue well above estimates, $21.153 million compared to $14.57 million.
The stock fell by more than 12 percent in the first few hours of Thursday's market to a low of $22.20. Shares finished the day at $22.62.
See how crowdsourced ratings could help you time the market.
Currently, the Vetr crowd's average target price for the stock is up at $22.32, which is still below the average analyst target price of $37.67. Less than 2 percent of Vetr users are holding JUNO in their watch lists.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.